The University of Chicago Header Logo

Connection

Sean Pitroda to Humans

Back to Details
This is a "connection" page, showing publications Sean Pitroda has written about Humans.
Sean Pitroda
Connection Strength
0.789
Humans
  1. Clinical and molecular correlates of tumor aneuploidy in metastatic non-small cell lung cancer. Sci Rep. 2024 08 21; 14(1):19375.
    View in: PubMed
    Score: 0.031
  2. Nontumor Cells in Tumor Samples Bias Expression-Based Models-Reply. JAMA Oncol. 2024 Feb 01; 10(2):260-261.
    View in: PubMed
    Score: 0.030
  3. Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1.
    View in: PubMed
    Score: 0.030
  4. Multidisciplinary Collaboration is Key. Int J Radiat Oncol Biol Phys. 2023 Dec 01; 117(5):1047-1048.
    View in: PubMed
    Score: 0.030
  5. STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2023 01; 7:e2200273.
    View in: PubMed
    Score: 0.028
  6. Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization. Neoplasia. 2023 Feb; 36:100867.
    View in: PubMed
    Score: 0.028
  7. Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022 12; 3(12):1498-1512.
    View in: PubMed
    Score: 0.028
  8. Tumor aneuploidy predicts survival following immunotherapy across multiple cancers. Nat Genet. 2022 12; 54(12):1782-1785.
    View in: PubMed
    Score: 0.028
  9. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
    View in: PubMed
    Score: 0.026
  10. Integrated molecular and clinical staging defines the spectrum of metastatic cancer. Nat Rev Clin Oncol. 2019 09; 16(9):581-588.
    View in: PubMed
    Score: 0.022
  11. Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncol. 2019 08; 20(8):e434-e442.
    View in: PubMed
    Score: 0.022
  12. Oligometastatic prostate cancer: Reality or figment of imagination? Cancer. 2019 02 01; 125(3):340-352.
    View in: PubMed
    Score: 0.021
  13. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018 05 04; 9(1):1793.
    View in: PubMed
    Score: 0.020
  14. JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers. Mol Cancer Ther. 2018 04; 17(4):732-739.
    View in: PubMed
    Score: 0.020
  15. Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4493-4500.
    View in: PubMed
    Score: 0.019
  16. DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy. Sci Transl Med. 2014 Mar 26; 6(229):229ra42.
    View in: PubMed
    Score: 0.015
  17. Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. PLoS One. 2012; 7(10):e46104.
    View in: PubMed
    Score: 0.014
  18. STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect. BMC Med. 2009 Nov 05; 7:68.
    View in: PubMed
    Score: 0.011
  19. MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci U S A. 2009 Apr 07; 106(14):5837-41.
    View in: PubMed
    Score: 0.011
  20. Emotional experience modulates brain activity during fixation periods between tasks. Neurosci Lett. 2008 Oct 03; 443(2):72-6.
    View in: PubMed
    Score: 0.010
  21. YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production. J Clin Invest. 2024 Dec 02; 134(23).
    View in: PubMed
    Score: 0.008
  22. DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. 2024 Dec; 25(8):e448-e452.
    View in: PubMed
    Score: 0.008
  23. Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials. Eur J Cancer. 2024 Sep; 209:114264.
    View in: PubMed
    Score: 0.008
  24. Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol. 2024 Aug; 25(8):e352-e362.
    View in: PubMed
    Score: 0.008
  25. Sharing the Burden: The Case for Definitive Local Therapy in Place of Immune Checkpoint Blockade for Patients With a Low-Volume Burden of Metastatic Disease. J Clin Oncol. 2024 Oct 10; 42(29):3387-3391.
    View in: PubMed
    Score: 0.008
  26. Radiotherapy and immunology. J Exp Med. 2024 Jul 01; 221(7).
    View in: PubMed
    Score: 0.008
  27. Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites. Clin Cancer Res. 2024 May 01; 30(9):1945-1958.
    View in: PubMed
    Score: 0.008
  28. Hormonal Therapy and Radiation Therapy in Prostate Cancer: 5-Year Outcomes From a Trial Evaluating Combined Androgen Blockade With 5-Alpha Reductase Inhibitors as an Alternative to Gonadotropin Releasing Hormone Agonists. Clin Genitourin Cancer. 2024 Aug; 22(4):102103.
    View in: PubMed
    Score: 0.008
  29. Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials. Int J Radiat Oncol Biol Phys. 2024 Apr 01; 118(5):1519-1530.
    View in: PubMed
    Score: 0.008
  30. Epitranscriptional regulation of TGF-ß pseudoreceptor BAMBI by m6A/YTHDF2 drives extrinsic radioresistance. J Clin Invest. 2023 12 15; 133(24).
    View in: PubMed
    Score: 0.007
  31. RNA m6A methylation and MDSCs: Roles and therapeutic implications for radiotherapy. Med. 2023 Dec 08; 4(12):863-874.
    View in: PubMed
    Score: 0.007
  32. Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial. JAMA Oncol. 2023 09 01; 9(9):1245-1254.
    View in: PubMed
    Score: 0.007
  33. Oligometastases: Characterizing the Role of Epigenetic Regulation of Epithelial-Mesenchymal Transition. Clin Cancer Res. 2023 08 01; 29(15):2761-2766.
    View in: PubMed
    Score: 0.007
  34. Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference. Oncoimmunology. 2023; 12(1):2222560.
    View in: PubMed
    Score: 0.007
  35. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023 07 10; 41(7):1294-1308.e8.
    View in: PubMed
    Score: 0.007
  36. Beyond the Visible Spectrum: Considering the Oligometastatic Hypothesis in the Light of a New Era. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):581-586.
    View in: PubMed
    Score: 0.007
  37. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2023 01 01; 115(1):202-213.
    View in: PubMed
    Score: 0.007
  38. The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol. 2022 09; 19(9):585-599.
    View in: PubMed
    Score: 0.007
  39. Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):645-654.
    View in: PubMed
    Score: 0.007
  40. Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2022 03 21; 29(4):225-239.
    View in: PubMed
    Score: 0.007
  41. Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy. Neoplasia. 2022 05; 27:100782.
    View in: PubMed
    Score: 0.007
  42. Radiotherapy and immunotherapy: open questions and future strategies. Trends Cancer. 2022 01; 8(1):9-20.
    View in: PubMed
    Score: 0.006
  43. Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus. Clin Cancer Res. 2021 10 01; 27(19):5188-5194.
    View in: PubMed
    Score: 0.006
  44. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
    View in: PubMed
    Score: 0.006
  45. Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold. Int J Mol Sci. 2021 Sep 03; 22(17).
    View in: PubMed
    Score: 0.006
  46. The Spectrum of Metastasis: An Opportunity for Cure? Semin Radiat Oncol. 2021 07; 31(3):174-179.
    View in: PubMed
    Score: 0.006
  47. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.006
  48. A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity. Cancer. 2021 08 01; 127(15):2631-2640.
    View in: PubMed
    Score: 0.006
  49. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021 02 24; 13(582).
    View in: PubMed
    Score: 0.006
  50. (Oligo)metastasis as a Spectrum of Disease. Cancer Res. 2021 05 15; 81(10):2577-2583.
    View in: PubMed
    Score: 0.006
  51. Oligometastasis: Past, Present, Future. Int J Radiat Oncol Biol Phys. 2020 11 01; 108(3):530-538.
    View in: PubMed
    Score: 0.006
  52. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
    View in: PubMed
    Score: 0.006
  53. Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):17-26.
    View in: PubMed
    Score: 0.006
  54. A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):189-195.
    View in: PubMed
    Score: 0.006
  55. Definition, Biology, and History of Oligometastatic and Oligoprogressive Disease. Cancer J. 2020 Mar/Apr; 26(2):96-99.
    View in: PubMed
    Score: 0.006
  56. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun. 2020 01 17; 11(1):338.
    View in: PubMed
    Score: 0.006
  57. Beyond Palliation: The Rationale for Metastasis-Directed Therapy for Metastatic Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 09; 14(9):1510-1512.
    View in: PubMed
    Score: 0.006
  58. Staging the Metastatic Spectrum Through Integration of Clinical and Molecular Features. J Clin Oncol. 2019 05 20; 37(15):1270-1276.
    View in: PubMed
    Score: 0.005
  59. DNA Methylation Controls Metastasis-Suppressive 14q32-Encoded miRNAs. Cancer Res. 2019 02 01; 79(3):650-662.
    View in: PubMed
    Score: 0.005
  60. Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. Clin Genitourin Cancer. 2019 Feb; 17(1):e12-e18.
    View in: PubMed
    Score: 0.005
  61. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
    View in: PubMed
    Score: 0.005
  62. Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones. J Vis Exp. 2016 11 30; (117).
    View in: PubMed
    Score: 0.005
  63. Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers. Sci Rep. 2016 10 24; 6:35854.
    View in: PubMed
    Score: 0.005
  64. DNA methylation by DNMT1 and DNMT3b methyltransferases is driven by the MUC1-C oncoprotein in human carcinoma cells. Oncogene. 2016 12 15; 35(50):6439-6445.
    View in: PubMed
    Score: 0.004
  65. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016 07 15; 122(14):2242-50.
    View in: PubMed
    Score: 0.004
  66. Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget. 2016 May 03; 7(18):26496-515.
    View in: PubMed
    Score: 0.004
  67. Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas. Cancer Res. 2016 Mar 15; 76(6):1538-48.
    View in: PubMed
    Score: 0.004
  68. Imaging of tumor clones with differential liver colonization. Sci Rep. 2015 Jun 22; 5:10946.
    View in: PubMed
    Score: 0.004
  69. microRNAs and oligometastasis. Aging (Albany NY). 2015 Mar; 7(3):146-7.
    View in: PubMed
    Score: 0.004
  70. 14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget. 2015 Feb 28; 6(6):3540-52.
    View in: PubMed
    Score: 0.004
  71. MUC1-C activates the TAK1 inflammatory pathway in colon cancer. Oncogene. 2015 Oct 01; 34(40):5187-97.
    View in: PubMed
    Score: 0.004
  72. RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation. Proc Natl Acad Sci U S A. 2014 Jan 28; 111(4):E484-91.
    View in: PubMed
    Score: 0.004
  73. Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells. PLoS One. 2012; 7(7):e39432.
    View in: PubMed
    Score: 0.003
  74. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):378-84.
    View in: PubMed
    Score: 0.003
  75. MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics. 2010 May 06; 3:16.
    View in: PubMed
    Score: 0.003
  76. Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-beta-dependent activation of antigen-specific CD8+ T cells. Mol Ther. 2010 May; 18(5):912-20.
    View in: PubMed
    Score: 0.003
  77. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene. 2010 Feb 11; 29(6):920-9.
    View in: PubMed
    Score: 0.003
  78. Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int J Radiat Biol. 2009 May; 85(5):421-31.
    View in: PubMed
    Score: 0.003
  79. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res. 2009 Apr 01; 69(7):2833-7.
    View in: PubMed
    Score: 0.003
  80. Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy. Cancer Gene Ther. 2009 Apr; 16(4):373-81.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.